Protocol Ledger

NCT07381764 · Phase II · RECRUITING

ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

Interventional Phase II clinical trial protocol NCT07381764 sponsored by Gruppo Oncologico Italia Meridionale in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-20 Enrollment: 150 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07381764
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07381764
Protocol FieldVerified Registry Value
NCT IdentifierNCT07381764
Consolidated Lead SponsorGruppo Oncologico Italia Meridionale
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment150 participants (ESTIMATED)
Registered Start Date2026-03-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07381764
Hospital Research SiteLocationSite Profile
ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyOpen Hospital Dossier ->
Istituto Europeo di OncologiaMilan, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI